Form 4 for TMCI TREACE MEDICAL CONCEPTS, INC.
Accepted 2024-09-17 00:00:00 ET · period of report 2024-09-17 · accession 0000950170-24-107401 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-17 | 2024-09-16 | TMCI | Treace John T. | CEO, Dir, 10% | P - Purchase | $5.31 | +50.0K | 6.52M | +0.8% | +$265.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | P | A | 50,000 | $5.31 | 6,523,095 | D | — | — | (F1) The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.0550 to $5.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. (F2) Includes 196,464 restricted stock units |